CMC Development Manager
Hubro Therapeutics
- Frist 13.1.2022
- Ansettelsesform Fast
HUBRO THERAPEUTICS IS LOOKING FOR CMC DEVELOPMENT MANAGER
Hubro Therapeutics is currently seeking for a CMC Manager who will take an active role in the further development of our products and the company.
Main Responsibilities
As CMC Manager you will provide chemistry, manufacturing and control expertise for our products in preclinical and clinical development.
You will be responsible for
Managing CMC development activities and supply for pre-clinical and clinical studies for the company’s lead candidates in development
Develop and lead relationships with contract development & manufacturing organisations (CDMOs and CROs)
Development of new drug substance and drug product manufacturing processes, formulations, analytical methods, stability documentation, validation of methods and processes
Provide CMC/quality documentation for regulatory submissions
Skills & Competencies
PhD or a MSc in chemistry, pharmacy, biotechnology or similar
Experience from CMC in pharmaceutical or biotech industry and R&D development
Knowledge about quality standards like GMP, ICH etc
Strong interpersonal and management skills and with the ability to build trustful relationships
Strong English communication skills
Management experience
Beneficial Requirements & Qualifications
Adaptability
Ability to work independently and at the same time be a good team player
Ability to find solution to complex challenges.
We can offer varied and exciting work in an innovative and dynamic biotech company. We promise you will develop professionally with challenging tasks in a growing company, as you participate in the development of novel cancer treatments. Some international travel and participation / presentation at science conferences and events can be expected.
Please send your CV and application in English to the email listed in the contact information as soon as possible and latest by January 13th, 2022.
For additional information please contact CTO Berit Iversen via e-mail as above or phone: +47 98 23 84 93 or CEO Jon Amund Eriksen on phone +47 95 08 59 14.
All applications will be treated confidentially.
Om arbeidsgiveren
Our lead candidate vaccine is FMPV-1 targets frameshift mutation in the transforming growth factor beta receptor 2 (TGFbR2) gene, frequently present in MSI-colorectal and stomach cancer as well as in hereditary colorectal cancer.
- Sektor: Privat
- Sted: Ullernchausseen 64, 0379 Oslo
- Bransje: Farmasi og legemiddel, Forskning, utdanning og vitenskap
- Stillingsfunksjon: Dokumentasjon, Produksjonsteknikk/Prosessteknikk, Prosjektledelse
Annonseinformasjon
- FINN-kode 241393313
- Sist endret